Please check your internet connection and try again.
# Calcium Acetate
## Overview
Calcium acetate is a phosphate binder used to control hyperphosphatemia in patients with chronic kidney disease (CKD).
## Primary Indications
* **Hyperphosphatemia:** Management of elevated serum phosphate levels in patients with end-stage renal disease (ESRD).
## Adult Dosing
* **Initial dose:** 2 tablets (667 mg calcium acetate per tablet, equivalent to 169 mg elemental calcium per tablet) orally with each meal.
* **Titration:** Dosage should be individualized based on serum phosphate levels. The goal is to reduce serum phosphate to < 6 mg/dL. Doses may range from 2 to 12 tablets per day.
* **Maximum dose:** While not explicitly defined by a hard maximum, doses are titrated to achieve target phosphate levels. Exceeding 12 tablets daily would typically require careful consideration and monitoring.
## Pediatric Dosing
* Dosing in pediatric patients is not well-established and should be managed by a physician experienced in pediatric nephrology.
## Dose Adjustments
* **Renal Impairment:** Dose must be adjusted based on serum phosphate levels and patient tolerance. Patients with CKD already have impaired renal function.
* **Hypercalcemia:** If hypercalcemia occurs, reduce the dose or discontinue the medication.
## Contraindications
* Hypercalcemia.
* Hypersensitivity to calcium acetate or any of its components.
## Adverse Effects
* **Common:** Hypercalcemia, constipation, nausea, vomiting, diarrhea, dyspepsia, abdominal pain.
* **Serious:** Cardiovascular events (arrhythmias) due to hypercalcemia, milk-alkali syndrome.
## Key Drug Interactions
* **Tetracyclines and Fluoroquinolones:** Calcium acetate can decrease the absorption of these antibiotics. Administer at least 2 hours before or 3 hours after the antibiotic.
* **Thyroid Hormones:** Calcium acetate may reduce the absorption of levothyroxine. Separate administration by at least 4 hours.
* **Antacids:** Concurrent use may increase the risk of hypercalcemia.
## Monitoring
* **Serum Phosphate:** Monitor regularly (e.g., weekly to monthly depending on clinical status) to guide dosing.
* **Serum Calcium:** Monitor regularly, especially in patients with a history of hypercalcemia or those taking other calcium-containing products. Target serum calcium is generally 8.5-10 mg/dL.
* **Alkaline Phosphatase:** May be monitored.
* **Signs and Symptoms of Hypercalcemia:** Educate patients to report symptoms such as nausea, vomiting, constipation, polyuria, polydipsia, weakness, and confusion.
## Clinical Pearls
* Administer with meals to effectively bind dietary phosphate.
* Ensure adequate hydration to help prevent constipation and reduce the risk of calcium-phosphate nephropathy.
* Titrate dose slowly and monitor serum levels closely to avoid both hyperphosphatemia and hypercalcemia.
* Educate patients about potential side effects and the importance of adhering to the prescribed regimen.
***
*This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and management may vary based on individual patient factors and local protocols.*
